GP130 activation induces myeloma and collaborates with MYC

Journal of Clinical Investigation

Volumn 124, Issue 12, 2014, Pages 5263-5274

  Dechow, Tobias ^a   Steidle, Sabine ^a   Götze, Katharina S ^a,b   Rudelius, Martina ^a,c   Behnke, Kerstin ^a   Pechloff, Konstanze ^a,b   Kratzat, Susanne ^a   Bullinger, Lars ^d   Fend, Falko ^e   Soberon, Valeria ^a   Mitova, Nadya ^a   Li, Zhoulei ^a   Thaler, Markus ^a   Bauer, Jan ^a   Pietschmann, Elke ^a   Albers, Corinna ^a   Grundler, Rebekka ^a   Schmidt Supprian, Marc ^a   Ruland, Jürgen ^a   Peschel, Christian ^a,b   Duyster, Justus ^a,f   Rose John, Stefan ^g   Bassermann, Florian ^a,b   Keller, Ulrich ^a,b   more..

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^c UNIVERSITY OF WÜRZBURG   (Germany)

^d UNIVERSITY HOSPITAL ULM   (Germany)

^e UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^f UNIVERSITY OF FREIBURG   (Germany)

^g UNIVERSITY OF KIEL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPROTEIN GP 130; JANUS KINASE; MYC PROTEIN; STAT3 PROTEIN; IL6ST PROTEIN, HUMAN; IL6ST PROTEIN, MOUSE; MYC PROTEIN, HUMAN; MYC PROTEIN, MOUSE; STAT3 PROTEIN, HUMAN; STAT3 PROTEIN, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL DIFFERENTIATION; CELL GROWTH; CONTROLLED STUDY; GENE ACTIVATION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; MULTIPLE MYELOMA; NONHUMAN; NUCLEOTIDE SEQUENCE; PATHOGENESIS; PHENOTYPE; PLASMA CELL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; ANIMAL; BAGG ALBINO MOUSE; CLINICAL TRIAL; EXPERIMENTAL NEOPLASM; FEMALE; GENETICS; MALE; METABOLISM; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; CELL LINE, TUMOR; CYTOKINE RECEPTOR GP130; FEMALE; HUMANS; MALE; MICE; MICE, INBRED BALB C; MULTIPLE MYELOMA; NEOPLASMS, EXPERIMENTAL; PLASMA CELLS; PROTO-ONCOGENE PROTEINS C-MYC; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR;

EID: 84915755914     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI69094     Document Type: Article

References (56)

1. Mahindra A, Laubach J, Raje N, Munshi N, Richardson PG, Anderson K. Latest advances and current challenges in the treatment of multiple myeloma. Nat Rev Clin Oncol. 2012;9(3):135-143.
2. Kapoor P, Rajkumar SV. Update on risk stratification and treatment of newly diagnosed multiple myeloma. Int J Hematol. 2011;94(4):310-320.
3. Palumbo A, Anderson K. Medical Progress Multiple Myeloma. New Engl J Med. 2011;364(11):1046-1060.
4. Chesi M, Bergsagel PL. Many multiple myelomas: making more of the molecular mayhem. Hematology Am Soc Hematol Educ Program. 2011;2011:344-353.
5. Fonseca R, et al. International Myeloma Working Group molecular classification of multiple myeloma: spotlight review. Leukemia. 2009;23(12):2210-2221.
6. Kuehl WM, Bergsagel PL. Molecular pathogenesis of multiple myeloma and its premalignant precursor. J Clin Invest. 2012;122(10):3456-3463.
7. Affer M, et al. Promiscuous MYC locus rearrangements hijack enhancers but mostly super-enhancers to dysregulate MYC expression in multiple myeloma. Leukemia. 2014;28(8):1725-1735.
8. Taga T, Kishimoto T. Signaling mechanisms through cytokine receptors that share signal transducing receptor components. Curr Opin Immunol. 1995;7(1):17-23.
9. Heinrich PC, et al. Membrane-bound and soluble interleukin-6 receptor: studies on structure, regulation of expression, and signal transduction. Ann N Y Acad Sci. 1995;762:222-236.
10. Imada K, Leonard WJ. The Jak-STAT pathway. Mol Immunol. 2000;37(1-2):1-11.
11. Hideshima T, Mitsiades C, Tonon G, Richardson PG, Anderson KC. Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets. Nat Rev Cancer. 2007;7(8):585-598.
12. Scuto A, et al. The novel JAK inhibitor AZD1480 blocks STAT3 and FGFR3 signaling, resulting in suppression of human myeloma cell growth and survival. Leukemia. 2011;25(3):538-550.
13. Monaghan KA, Khong T, Burns CJ, Spencer A. The novel JAK inhibitor CYT387 suppresses multiple signalling pathways, prevents proliferation and induces apoptosis in phenotypically diverse myeloma cells. Leukemia. 2011;25(12):1891-1899.
14. Yasui H, Hideshima T, Richardson PG, Anderson KC. Novel therapeutic strategies targeting growth factor signalling cascades in multiple myeloma. Br J Haematol. 2006;132(4):385-397.
15. Pedranzini L, et al. Pyridone 6, a pan-Janus-activated kinase inhibitor, induces growth inhibition of multiple myeloma cells. Cancer Res. 2006;66(19):9714-9721.
16. Kovalchuk AL, et al. IL-6 transgenic mouse model for extraosseous plasmacytoma. Proc Natl Acad Sci U S A. 2002;99(3):1509-1514.
17. Adams JM, et al. The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice. Nature. 1985;318(6046):533-538.
18. Carrasco DR, et al. The differentiation and stress response factor XBP-1 drives multiple myeloma pathogenesis. Cancer Cell. 2007;11(4):349-360.
19. Dauer DJ, et al. Stat3 regulates genes common to both wound healing and cancer. Oncogene. 2005;24(21):3397-3408.
20. Chapman MA, et al. Initial genome sequencing and analysis of multiple myeloma. Nature. 2011;471(7339):467-472.
21. Zhan F, et al. The molecular classification of multiple myeloma. Blood. 2006;108(6):2020-2028.
22. Gearing DP, et al. Proliferative responses and binding properties of hematopoietic cells transfected with low-affinity receptors for leukemia inhibitory factor, oncostatin M, and ciliary neurotrophic factor. Proc Natl Acad Sci U S A. 1994;91(3):1119-1123.
23. Stuhlmann-Laeisz C, et al. Forced dimerization of gp130 leads to constitutive STAT3 activation, cytokine-independent growth, and blockade of differentiation of embryonic stem cells. Mol Biol Cell. 2006;17(7):2986-2995.
24. Miething C, et al. The oncogenic fusion protein nucleophosmin-anaplastic lymphoma kinase (NPM-ALK) induces two distinct malignant phenotypes in a murine retroviral transplantation model. Oncogene. 2003;22(30):4642-4647.
25. Swerdlow SHC, et al., eds. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: International Agency for Research on Cancer; 2008.
26. Rawstron AC, et al. Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disorders. Haematologica. 2008;93(3):431-438.
27. Guikema JEJ, Hovenga S, Vellenga E, Bos NA. Heterogeneity in the multiple myeloma tumor clone. Leuk Lymphoma. 2004;45(5):857-871.
28. Li J, et al. INCB16562, a JAK1/2 selective inhibitor, is efficacious against multiple myeloma cells and reverses the protective effects of cytokine and stromal cell support. Neoplasia. 2010;12(1):28-38.
29. Oostendorp RA, et al. Stromal cell lines from mouse aorta-gonads-mesonephros subregions are potent supporters of hematopoietic stem cell activity. Blood. 2002;99(4):1183-1189.
30. Rangarajan A, Weinberg RA. Opinion - Comparative biology of mouse versus human cells: modelling human cancer in mice. Nat Rev Cancer. 2003;3(12):952-959.
31. Keller U, et al. Myc suppression of Nfkb2 accelerates lymphomagenesis. BMC Cancer. 2010;10:348.
32. Old JB, et al. Skp2 directs Myc-mediated suppression of p27Kip1 yet has modest effects on Myc-driven lymphomagenesis. Mol Cancer Res. 2010;8(3):353-362.
33. den Hollander J, et al. Aurora kinases A and B are up-regulated by Myc and are essential for maintenance of the malignant state. Blood. 2010;116(9):1498-1505.
34. Bouchard C, Lee S, Paulus-Hock V, Loddenkemper C, Eilers M, Schmitt CA. FoxO transcription factors suppress Myc-driven lymphomagenesis via direct activation of Arf. Genes Dev. 2007;21(21):2775-2787.
35. Chauhan D, et al. Multiple myeloma cell adhesion-induced interleukin-6 expression in bone marrow stromal cells involves activation of NF-κB. Blood. 1996;87(3):1104-1112.
36. Kawano M, et al. Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas. Nature. 1988;332(6159):83-85.
37. Pulkki K, Pelliniemi TT, Rajamaki A, Tienhaara A, Laakso M, Lahtinen R. Soluble interleukin-6 receptor as a prognostic factor in multiple myeloma. Finnish Leukaemia Group. Br J Haematol. 1996;92(2):370-374.
38. Bataille R, Jourdan M, Zhang XG, Klein B. Serum levels of interleukin 6, a potent myeloma cell growth factor, as a reflect of disease severity in plasma cell dyscrasias. J Clin Invest. 1989;84(6):2008-2011.
39. Sporeno E, et al. Human interleukin-6 receptor super-antagonists with high potency and wide spectrum on multiple myeloma cells. Blood. 1996;87(11):4510-4519.
40. Catlett-Falcone R, et al. Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity. 1999;10(1):105-115.
41. Chatterjee M, Stuhmer T, Herrmann P, Bommert K, Dorken B, Bargou RC. Combined disruption of both the MEK/ERK and the IL-6R/STAT3 pathways is required to induce apoptosis of multiple myeloma cells in the presence of bone marrow stromal cells. Blood. 2004;104(12):3712-3721.
42. Chatterjee M, et al. In the presence of bone marrow stromal cells human multiple myeloma cells become independent of the IL-6/gp130/STAT3 pathway. Blood. 2002;100(9):3311-3318.
43. Brocke-Heidrich K, et al. Interleukin-6-dependent gene expression profiles in multiple myeloma INA-6 cells reveal a Bcl-2 family-independent survival pathway closely associated with Stat3 activation. Blood. 2004;103(1):242-251.
44. Quintanilla-Martinez L, et al. Analysis of signal transducer and activator of transcription 3 (Stat 3) pathway in multiple myeloma: Stat 3 activation and cyclin D1 dysregulation are mutually exclusive events. Am J Pathol. 2003;162(5):1449-1461.
45. Yu H, Pardoll D, Jove R. STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer. 2009;9(11):798-809.
46. Maclean KH, Keller UB, Rodriguez-Galindo C, Nilsson JA, Cleveland JL. c-Myc augments gamma irradiation-induced apoptosis by suppressing Bcl-XL. Mol Cell Biol. 2003;23(20):7256-7270.
47. Cheung WC, et al. Novel targeted deregulation of c-Myc cooperates with Bcl-X(L) to cause plasma cell neoplasms in mice. J Clin Invest. 2004;113(12):1763-1773.
48. Cheung WC, Van Ness B. Distinct IL-6 signal transduction leads to growth arrest and death in B cells or growth promotion and cell survival in myeloma cells. Leukemia. 2002;16(6):1182-1188.
49. Yata K, Yaccoby S. The SCID-rab model: a novel in vivo system for primary human myeloma demonstrating growth of CD138-expressing malignant cells. Leukemia. 2004;18(11):1891-1897.
50. Chesi M, et al. AID-dependent activation of a MYC transgene induces multiple myeloma in a conditional mouse model of post-germinal center malignancies. Cancer Cell. 2008;13(2):167-180.
51. Keller UB, et al. Myc targets Cks1 to provoke the suppression of p27Kip1, proliferation and lymphomagenesis. EMBO J. 2007;26(10):2562-2574.
52. Miething C, et al. The Bcr-Abl mutations T315I and Y253H do not confer a growth advantage in the absence of imatinib. Leukemia. 2006;20(4):650-657.
53. Kratzat S, et al. Cks1 is required for tumor cell proliferation but not sufficient to induce hematopoietic malignancies. PLoS One. 2012;7(5):e37433.
54. Luck SC, et al. Deregulated apoptosis signaling in core-binding factor leukemia differentiates clinically relevant, molecular marker-independent subgroups. Leukemia. 2011;25(11):1728-1738.
55. Subramanian A, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005;102(43):15545-15550.
56. Machulla HJ, Blocher A, Kuntzsch M, Piert M, Wei R, Grierson J. Simplified labeling approach for synthesizing 3-deoxy-3-[18F] fluorothymidine ([18F] FLT). J Radioanal Nucl Chem. 2000;243(3):843-846.